Eosinophil lowering agent
Reading File
Finding Sources
Searching PubMed
eosinophilia AND treatment
Searching the Web
eosinophil lowering agents anti IL-5 benralizumab FDA approved indications
Eosinophil-lowering agents include:
- Benralizumab: anti-IL-5 receptor-alpha monoclonal antibody. It directly depletes eosinophils and is often the strongest eosinophil-lowering biologic.
- Mepolizumab and reslizumab: anti-IL-5 monoclonal antibodies that reduce eosinophil survival and activity.
- Systemic corticosteroids such as prednisone: lower eosinophils quickly, but long-term use has substantial adverse effects.
- Depending on the disease, dupilumab may help control eosinophilic inflammation, although blood eosinophils can transiently rise early in treatment.
These biologics are used for specific conditions such as severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or selected eosinophilic gastrointestinal diseases. They are not used solely for an elevated eosinophil count without identifying the cause, which may include allergy, drug reaction, parasitic infection, autoimmune disease, or a hematologic disorder.
For severe eosinophilic asthma, anti-IL-5 pathway therapies include mepolizumab, reslizumab, and benralizumab; benralizumab targets the receptor and causes eosinophil depletion. FDA clinical review
Anti inflammatory agents
Reading File
Finding Sources
Searching PubMed
anti-inflammatory drugs AND systematic review
Searching the Web
NIH anti-inflammatory medicines NSAIDs corticosteroids overview
Anti-inflammatory agents reduce inflammation, swelling, pain, and sometimes immune activity.
| Class | Examples | Typical uses | Important risks |
|---|---|---|---|
| NSAIDs | Ibuprofen, naproxen, diclofenac, indomethacin, celecoxib | Musculoskeletal pain, arthritis, dysmenorrhea, gout | Gastritis/ulcer or bleeding, kidney injury, fluid retention, increased cardiovascular risk |
| Corticosteroids | Prednisone, prednisolone, dexamethasone, hydrocortisone; inhaled budesonide | Asthma/COPD exacerbations, allergic, autoimmune, and inflammatory diseases | With longer systemic use: infection, hyperglycemia, osteoporosis, adrenal suppression, mood changes |
| Topical anti-inflammatory drugs | Diclofenac gel, topical corticosteroids such as hydrocortisone | Local joint, muscle, or skin inflammation | Usually fewer systemic effects; skin thinning can occur with prolonged topical steroid use |
| Disease-modifying agents | Methotrexate, hydroxychloroquine, sulfasalazine | Rheumatoid arthritis and related inflammatory disorders | Require clinician monitoring for organ and blood-count toxicity |
| Biologic/targeted agents | TNF inhibitors, IL-6 inhibitors, JAK inhibitors, anti-IL-5 agents | Moderate-severe autoimmune or eosinophilic inflammatory disease | Infection risk and condition-specific monitoring |
NSAIDs work mainly by inhibiting cyclooxygenase enzymes and lowering prostaglandin production. Corticosteroids have broader anti-inflammatory and immunosuppressive effects. NIH overview of NSAIDs and corticosteroids.
Choice depends on the cause and site of inflammation. Do not combine NSAIDs without medical advice, and use extra caution if there is kidney disease, peptic ulcer/bleeding history, anticoagulant use, heart failure, pregnancy, or uncontrolled hypertension.
This is a shared conversation. Sign in to Orris to start your own chat.